Indefinite Delivery Contract SPE2DR25D9958

Award Date 11/13/25
Last Date to Order 12/31/26
Ultimate Awardee
Not listed
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
This Indefinite Delivery Contract (IDC) awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business, provides a comprehensive range of pharmaceutical products and medical supplies to support the recurring medical needs of military healthcare facilities and veterans' medical centers nationwide. The $499,999,999 single-award IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for branded and generic prescription...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $499,999,999, covers the delivery of a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the medical supply needs of military health facilities worldwide. The contract...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, to provide a comprehensive range of pharmaceutical products and medical supplies to support the medical needs of Department of Defense (DoD) healthcare facilities worldwide. The IDC, valued at $499,999,999 and valid through November 2026, enables DLA to issue firm fixed-price delivery orders for branded and generic...
This indefinite delivery contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The $499,999,999 single-award IDC enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the recurring medical supply needs of military healthcare facilities...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $499,999,999, covers a wide range of pharmaceutical products and medical supplies to support the recurring medical needs of military healthcare facilities and veterans' medical centers nationwide. The contract enables the DLA to issue firm fixed-price delivery orders for branded and generic...
The Indefinite Delivery Contract (IDC) award to DMS Pharmaceutical Group Inc., a woman-owned small business, by the Defense Logistics Agency (DLA) aims to establish a single-award, Firm Fixed Price contract to provide a comprehensive range of pharmaceutical products to support the medical supply needs of military health facilities worldwide. The $499,999,999 IDC, valid through November 2026, encompasses branded and generic prescription drugs, over-the-counter medications, biologics, and...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, to provide a comprehensive range of pharmaceutical products and medical supplies to support the recurring medical needs of military healthcare facilities and veterans' medical centers nationwide. The $499,999,999 single-award IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $499,999,999 single-award contract covers a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the recurring medical supply needs of military healthcare facilities and veterans' medical centers...
This Indefinite Delivery Contract (IDC) awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business, aims to provide a comprehensive range of pharmaceutical products and medical supplies to support the recurring medical needs of military healthcare facilities and veterans' medical centers nationwide. The $499,999,999 single-award IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for branded and generic...
This indefinite delivery contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $499,999,999 IDC has a period of performance through November 2026 and enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products to support the medical supply needs of military health facilities worldwide. The contracted products include branded and generic...

The provided Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The single-award IDC, valued at $499,999,999, covers a comprehensive range of pharmaceutical products including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the recurring medical supply needs of military healthcare facilities and veterans' medical centers nationwide.

The IDC was established under the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) solicitation, which aims to provide worldwide pharmaceutical support to various Department of Defense (DoD) customers, the U.S. Coast Guard, Designated Providers, and Other Government Agencies. The contract has a 30-month base period with three 30-month option periods, for a total potential period of performance through November 2026. The acquisition is unrestricted, with the intention to make multiple regional awards to at least three different contractors to ensure resilience and access to vital pharmaceuticals during contingencies or natural disasters.

Generated 6/6/25, 10:01 AM